Autologous Bone Marrow Transplantation in Acute Leukemia

Dicke, Karel A.; Vellekoop, Lijda; Zander, Axel R.; Jagannath, Sundar; Poynton, Christopher H.; Lichtiger, Benjamin; Verma, Dharmvir S.; Spitzer, Gary

doi:10.1159/000156967

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, local virus application is generally not a particularly feasible therapy for many hematological cancers, and therefore i n vivo applications of oncolytic viruses need to be designed with systemic administration in mind. Combination chemotherapy and HSCT is an effective therapy for hematological malignancies, and autologous transplantation is particularly important, given widespread use in the treatment of multiple myeloma and lymphoma [61–63]. …”

Section: B Oncolytic Viruses and Applications In Hematological Maligmentioning

confidence: 99%

“…HSCT combined with chemotherapy has been performed for hematological malignancies, and autologous HSCT is frequently performed in certain diseases with efficacy and safety, including no risk of graft versus host disease (GVHD)[61–63]. However, one potential drawback of using autologous stem cells is the risk of contamination of the stem cell graft with malignant cells[66].…”

Section: B Oncolytic Viruses and Applications In Hematological Maligmentioning

confidence: 99%

See 1 more Smart Citation

Gene and virotherapy for hematological malignancies

Domingo-Musibay

Yamamoto

2016

Int J Hematol

View full text Add to dashboard Cite

Treatment of the hematological malignancies has undergone recent transformation. Advances in gene therapy and molecular techniques, as well as significant gains in computational abilities have supported rapid development of safer and better tolerated therapies for many patients with hematologic cancers. In this review, we discuss novel applications of gene therapy including immunomodulation and gene silencing, and report on the rise of oncolytic viruses to treat malignancies arising in cells of the blood, lymph, and marrow. We discuss the relationship of the tropism of wild-type viruses and their oncolytic behavior as well as tumoricidal and immunostimulatory properties of several attenuated and recombinant viruses in clinical development worldwide. While we have focused on promising virotherapy applications for future development, we also present a historical perspective and identify areas of potential clinical and regulatory practice change. Several of the virus systems being developed for hematogic application are outlined and efficacy data is summarized and presented in the context of ongoing or future human clinical testing. Advantages and limitations of gene and virus therapy are presented to readers including challenges and opportunities to improve treatment tolerability and outcomes for patients with hematologic malignancy.

show abstract

Section: B Oncolytic Viruses and Applications In Hematological Maligmentioning

confidence: 99%

Section: B Oncolytic Viruses and Applications In Hematological Maligmentioning

confidence: 99%

Gene and virotherapy for hematological malignancies

Domingo-Musibay

Yamamoto

2016

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…Finally, a specific journal, Bone Marrow Transplantation, is being published since 1986. AutoBMT has a shorter history, but is developing an equally impressive list of monographs [35,36], symposia proceedings and reviews [37][38][39]. Very rapid progress, new drugs and procedures, and the resulting changes of philosophies and attitudes, all contribute to making the whole field of BMT extremely variable.…”

Section: Increasing Use Of Bmtmentioning

confidence: 99%

Bone Marrow Transplantation

Marmont¹

1990

New Approaches to the Treatment of Leukemia

View full text Add to dashboard Cite

“…Introduction Recently, monoclonal antibodies directed at normal differentiation antigens present on leukemic cells have been prepared (1,2). Certain of these antibodies have been used therapeutically in an attempt to purge malignant cells from marrow in vitro before autologous marrow transplantation (3)(4)(5). The present study was done to determine whether lysis of hematopoietic cells from patients with acute myeloid leukemia (AML)' with a monoclonal antibody that recognizes normal colony-forming cells and leukemic blast cells would kill leukemic progenitors without affecting all normal progenitors.…”

mentioning

confidence: 99%

Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.

Bernstein¹,

Singer²,

Andrews³

et al. 1987

J. Clin. Invest.

View full text Add to dashboard Cite

Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone.

show abstract

Autologous Bone Marrow Transplantation in Acute Leukemia

Cited by 5 publications

References 11 publications

Gene and virotherapy for hematological malignancies

Gene and virotherapy for hematological malignancies

Bone Marrow Transplantation

Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed.

Contact Info

Product

Resources

About